Harrow, Inc. $HROW Shares Sold by Trexquant Investment LP

Key Points

• Trexquant Investment LP sold 84,853 shares of Harrow, Inc., reducing its holdings by 89.8% during the first quarter, leaving the firm with 9,647 shares valued at approximately $257,000.
• Several analysts have issued favorable ratings on Harrow's stock, with Cantor Fitzgerald setting a price target of $76.00, and the current consensus rating being "Buy" with a target price of $64.67.
• Harrow reported a quarterly EPS of $0.24, significantly surpassing analysts' estimates, although the company also faced challenges with revenue slightly below expectations.

Trexquant Investment LP lessened its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 89.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,647 shares of the company's stock after selling 84,853 shares during the period. Trexquant Investment LP's holdings in Harrow were worth $257,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in Harrow during the 4th quarter worth approximately $25,000. Tower Research Capital LLC TRC lifted its stake in Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after acquiring an additional 1,462 shares during the period. Pale Fire Capital SE acquired a new stake in Harrow during the 1st quarter valued at approximately $216,000. Rafferty Asset Management LLC acquired a new stake in Harrow during the 4th quarter valued at approximately $270,000. Finally, Fox Run Management L.L.C. acquired a new stake in Harrow during the 1st quarter valued at approximately $282,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. BTIG Research lifted their price objective on shares of Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Zacks Research upgraded shares of Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Cantor Fitzgerald initiated coverage on shares of Harrow in a research note on Friday, July 11th. They issued an "overweight" rating and a $76.00 target price for the company. HC Wainwright boosted their target price on shares of Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Finally, William Blair initiated coverage on shares of Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating for the company. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $64.67.

Harrow Trading Down 0.1%

HROW traded down $0.03 during midday trading on Friday, hitting $39.42. 461,281 shares of the company traded hands, compared to its average volume of 463,590. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. Harrow, Inc. has a 52-week low of $20.85 and a 52-week high of $59.23. The business has a 50 day simple moving average of $36.12 and a two-hundred day simple moving average of $30.00.

Harrow (NASDAQ:HROW - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. The business had revenue of $63.74 million during the quarter, compared to analysts' expectations of $64.23 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. Harrow has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Harrow, Inc. will post -0.53 EPS for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.